%0 Journal Article
%T Pemetrexed had significantly better clinical efficacy in patients with stage IV lung adenocarcinoma with susceptible EGFR mutations receiving platinum-based chemotherapy after developing resistance to the first-line gefitinib treatment
%A Chih-Jen Yang
%A Inn-Wen Chong
%A Jen-Yu Hung
%A Jui-Sheng Hsu
%A Jui-Ying Lee
%A Ming-Ju Tsai
%A Ming-Shyan Huang
%A Shah-Hwa Chou
%A Ta-Chih Liu
%A Ying-Ming Tsai
%J Archive of "OncoTargets and therapy".
%D 2016
%R 10.2147/OTT.S100164
%X Increased evidences show that epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors such as gefitinib could prolong progression-free survival (PFS) compared with cytotoxic chemotherapy for metastatic lung nonsquamous cell carcinoma harboring susceptible EGFR mutation, and gefitinib was served as the first-line therapy. However, acquired resistance is inevitable, but the salvage therapies are still unclear
%K epidermal growth factor receptor
%K gefitinib
%K acquired resistance
%K pemetrexed
%K chemotherapy
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4803239/